Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | PREP | P48147 | 1/20 | 0.45 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2393741 | 0.86 | SMN1; SMN2 (0.46) | SMN1; SMN2NPC1RAB9AHTR2CCYP2C19 | |
| SCHEMBL2394393 | 0.85 | ACE2 (0.47) | SMN1; SMN2NPC1RAB9AHTR2CCYP2C19 | |
| SCHEMBL2388726 | 0.85 | ACE2 (0.47) | SMN1; SMN2NPC1RAB9AHTR2CCYP2C19 | |
| SCHEMBL1643460 | 0.85 | HTR2C (0.51) | SMN1; SMN2NPC1RAB9AHTR2CCYP2C19 | |
| SCHEMBL2393739 | 0.82 | PDK1 (0.51) | SMN1; SMN2NPC1RAB9AHTR2CCYP2C19 | |
| SCHEMBL2389658 | 0.81 | HTR2C (0.48) | SMN1; SMN2NPC1RAB9AHTR2CCYP2C19 | |
| SCHEMBL2395087 | 0.80 | HTR2C (0.46) | SMN1; SMN2NPC1RAB9AHTR2CCYP2C19 | |
| SCHEMBL6745607 | 0.79 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9AHTR2CCYP2C19 | |
| SCHEMBL19506503 | 0.77 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9AHTR2CCYP2C19 | |
| SCHEMBL2211932 | 0.77 | SMN1; SMN2 (0.49) | SMN1; SMN2NPC1RAB9AHTR2CCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2098507-B1 | Cyclic amine compound as androgen receptor modulator | TAKEDA PHARMACEUTICAL (JP) | 2014-11-12 | — | — | EP | disclosed |
| US-8013008-B2 | Cyclic amine compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-06 | — | — | US | disclosed |
| US-8013008-B2 | Cyclic amine compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-06 | — | — | US | disclosed |
| US-8013008-B2 | Cyclic amine compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-06 | — | — | US | disclosed |
| US-20100087506-A1 | CYCLIC AMINE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| US-20100087506-A1 | CYCLIC AMINE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087506-A1 | CYCLIC AMINE COMPOUND | AR, FSHR, NR5A1 | SMN1; SMN2 3154/4885NPC1 2764/4885RAB9A 2308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.